Vladimir Perkov
Overview
Explore the profile of Vladimir Perkov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lemdani K, Marlin R, Mayet C, Perkov V, Pascal Q, Ripoll M, et al.
NPJ Vaccines
. 2024 Jun;
9(1):113.
PMID: 38902327
The characterization of vaccine distribution to relevant tissues after in vivo administration is critical to understanding their mechanisms of action. Vaccines based on mRNA lipid nanoparticles (LNPs) are now being...
2.
Broudic K, Laurent S, Perkov V, Simon C, Garinot M, Truchot N, et al.
J Appl Toxicol
. 2023 Sep;
44(3):371-390.
PMID: 37723625
Messenger RNA (mRNA) vaccines have demonstrated efficacy against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in humans. mRNA technology holds tremendous potential for rapid control and prevention of emergencies due to...
3.
Bernard M, Bazin E, Petiot N, Lemdani K, Commandeur S, Verdelet C, et al.
Mol Ther Nucleic Acids
. 2023 Jun;
32:794-806.
PMID: 37346973
The use of modified nucleosides is an important approach to mitigate the intrinsic immunostimulatory activity of exogenous mRNA and to increase its translation for mRNA therapeutic applications. However, for vaccine...
4.
Ripoll M, Bernard M, Vaure C, Bazin E, Commandeur S, Perkov V, et al.
Biomaterials
. 2022 May;
286:121570.
PMID: 35576809
The mRNA vaccine technology has promising applications to fight infectious diseases as demonstrated by the licensing of two mRNA-based vaccines, Comirnaty® (Pfizer/BioNtech) and Spikevax® (Moderna), in the context of the...